158 related articles for article (PubMed ID: 1381608)
1. Surface marker expression in acute myeloid leukaemia at first relapse.
Thomas X; Campos L; Archimbaud E; Shi ZH; Treille-Ritouet D; Anglaret B; Fiere D
Br J Haematol; 1992 May; 81(1):40-4. PubMed ID: 1381608
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukaemia with an unusual phenotype: myeloperoxidase (+), CD13 (-), CD14 (-) and CD33 (-).
Seshi B; Kashyap A; Bennett JM
Br J Haematol; 1992 Jul; 81(3):374-7. PubMed ID: 1382546
[TBL] [Abstract][Full Text] [Related]
3. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
4. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy.
Campos L; Guyotat D; Archimbaud E; Devaux Y; Treille D; Larese A; Maupas J; Gentilhomme O; Ehrsam A; Fiere D
Br J Haematol; 1989 Jun; 72(2):161-6. PubMed ID: 2757962
[TBL] [Abstract][Full Text] [Related]
5. CD4+, CD33-, CD13-, CD14- acute monoblastic leukaemia.
Lombard EH; Mansvelt EP
Acta Haematol; 1992; 87(3):151-2. PubMed ID: 1379402
[TBL] [Abstract][Full Text] [Related]
6. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.
Virgo P; Denning-Kendall PA; Erickson-Miller CL; Singha S; Evely R; Hows JM; Freeman SD
Br J Haematol; 2003 Nov; 123(3):420-30. PubMed ID: 14617000
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype.
Alsabeh R; Brynes RK; Slovak ML; Arber DA
Am J Clin Pathol; 1997 Apr; 107(4):430-7. PubMed ID: 9124211
[TBL] [Abstract][Full Text] [Related]
8. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).
Baer MR; Stewart CC; Dodge RK; Leget G; Sulé N; Mrózek K; Schiffer CA; Powell BL; Kolitz JE; Moore JO; Stone RM; Davey FR; Carroll AJ; Larson RA; Bloomfield CD
Blood; 2001 Jun; 97(11):3574-80. PubMed ID: 11369653
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of cell marker analysis in de novo acute myeloid leukemia.
Del Poeta G; Stasi R; Venditti A; Suppo G; Aronica G; Bruno A; Masi M; Tabilio A; Papa G
Leukemia; 1994 Mar; 8(3):388-94. PubMed ID: 7907393
[TBL] [Abstract][Full Text] [Related]
10. [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
Jiang NG; Chen XM; Zhu HL; Zhong L; Zeng TT; Jia YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1405-9. PubMed ID: 21176339
[TBL] [Abstract][Full Text] [Related]
11. Myeloid antigen, CD13, CD14, and/or CD33 expression is restricted to certain lymphoid neoplasms.
Nakase K; Kita K; Shiku H; Tanaka I; Nasu K; Dohy H; Kyo T; Tsutani H; Kamada N
Am J Clin Pathol; 1996 Jun; 105(6):761-8. PubMed ID: 8659452
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87.
Creutzig U; Harbott J; Sperling C; Ritter J; Zimmermann M; Löffler H; Riehm H; Schellong G; Ludwig WD
Blood; 1995 Oct; 86(8):3097-108. PubMed ID: 7579404
[TBL] [Abstract][Full Text] [Related]
13. Role of blast cell immunophenotyping for the diagnosis and prognosis of acute myeloid leukemia.
Dubosc-Marchenay N; Lacombe F; Dumain P; Marit G; Montastruc M; Belloc F; Reiffers J
Hematol Oncol; 1992; 10(5):235-49. PubMed ID: 1493908
[TBL] [Abstract][Full Text] [Related]
14. Expression patterns of CD33 and CD15 predict outcome in patients with acute myeloid leukemia.
Derolf AR; Björklund E; Mazur J; Björkholm M; Porwit A
Leuk Lymphoma; 2008 Jul; 49(7):1279-91. PubMed ID: 18604716
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of CD13 and CD33 expression at relapse on acute myeloid leukemia cells with an unusual phenotype: MPO+CD13-CD33-.
Kawada H; Ichikawa Y; Kobayashi N; Fukuda R; Yonekura S; Nagao T
Intern Med; 1993 Sep; 32(9):733-6. PubMed ID: 7908235
[TBL] [Abstract][Full Text] [Related]
16. Enhanced myeloid specificity of CD117 compared with CD13 and CD33.
Nomdedéu JF; Mateu R; Altès A; Llorente A; Rio C; Estivill C; López O; Ubeda J; Rubiol E
Leuk Res; 1999 Apr; 23(4):341-7. PubMed ID: 10229319
[TBL] [Abstract][Full Text] [Related]
17. The value of detecting surface and cytoplasmic antigens in acute myeloid leukaemia.
Urbano-Ispizua A; Matutes E; Villamor N; Sierra J; Pujades A; Reverter JC; Feliu E; Cervantes F; Vives-Corrons JL; Montserrat E
Br J Haematol; 1992 Jun; 81(2):178-83. PubMed ID: 1322689
[TBL] [Abstract][Full Text] [Related]
18. [The use of monoclonal antibodies for immunologic typing and prognosis prediction in acute non-lymphoblastic leukemia].
Chen GB; Tang MH; Yang TY
Zhonghua Nei Ke Za Zhi; 1993 Jun; 32(6):405-8. PubMed ID: 7903627
[TBL] [Abstract][Full Text] [Related]
19. Expression of myeloid differentiation antigens in acute nonlymphocytic leukemia: increased concentration of CD33 antigen predicts poor outcome--a report from the Childrens Cancer Study Group.
Dinndorf PA; Buckley JD; Nesbit ME; Lampkin BC; Piomelli S; Feig SA; Kersey JH; Hammond GD; Bernstein ID
Med Pediatr Oncol; 1992; 20(3):192-200. PubMed ID: 1574028
[TBL] [Abstract][Full Text] [Related]
20. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
Matsui H; Takeshita A; Naito K; Shinjo K; Shigeno K; Maekawa M; Yamakawa Y; Tanimoto M; Kobayashi M; Ohnishi K; Ohno R
Leukemia; 2002 May; 16(5):813-9. PubMed ID: 11986941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
